60 Degrees Pharmaceuticals (SCTP) investor relations material

Executive summary

• Focused on developing and commercializing therapies for infectious diseases, with Arakoda® as the lead marketed product for malaria prevention.

• Pipeline includes tafenoquine-based products and Australian Chestnut Extract.

• Key partnerships formed with Runway Health and GoodRx to expand access and savings for Arakoda.

• All three patients in a babesiosis trial were cured, and a New Dietary Ingredient Notification was submitted for Australian Chestnut Extract.

• Continued commercialization of ARAKODAⓇ (tafenoquine) in the U.S. and Australia, with ongoing collaborations with research and academic organizations.

Financial highlights

• Product revenues for Q1 2026 were $162,092, down 0.89% year-over-year; gross profit was $76,377, with a gross margin of 47.12%, down from 55.20%.

• Net loss attributed to common stockholders was $2,208,584, or $1.28 per share, compared to $2,004,611, or $6.25 per share, in Q1 2025.

• Cash and cash equivalents increased to $3,337,760 as of March 31, 2026, from $1,510,065 at year-end 2025.

• Net cash used in operating activities was $2,741,559, up 71.63% year-over-year.

• Operating expenses rose to $2.17 million in Q1 2026 from $2.09 million in Q1 2025.

Outlook and guidance

• Management expects current cash to last through mid-September 2026, with substantial doubt about the ability to continue as a going concern for the next 12 months without additional capital.

• Plans to fund operations through further equity/debt financing or business development transactions, but no assurance of success.